{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:58:52Z","timestamp":1791305932902,"version":"4.3.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":3840,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1111\/j.1538-7836.2012.04720.x","type":"journal-article","created":{"date-parts":[[2012,4,3]],"date-time":"2012-04-03T13:00:06Z","timestamp":1333458006000},"page":"992-997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Sex hormone\u2010binding globulin as a marker for the thrombotic risk of hormonal contraceptives"],"prefix":"10.1016","volume":"10","author":[{"given":"M.","family":"RAPS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"HELMERHORST","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"FLEISCHER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"THOMASSEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"ROSENDAAL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"ROSING","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"BALLIEUX","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"VAN VLIET","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0010","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJM200105173442007","article-title":"Oral contraceptives and the risk of venous thrombosis","volume":"344","author":"Vandenbroucke","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0015","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1046\/j.1538-7836.2003.00264.x","article-title":"Estrogens, progestogens and thrombosis","volume":"1","author":"Rosendaal","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0020","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case\u2013control study","volume":"339","author":"van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0025","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0140-6736(95)91929-5","article-title":"Enhancement by factor\u00a0V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a thirdgeneration progestagen","volume":"346","author":"Bloemenkamp","year":"1995","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0030","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"346","year":"1995","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0035","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow\u2010up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0040","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","article-title":"Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components","volume":"346","author":"Jick","year":"1995","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1538-7836.2010.04148.x","article-title":"Hormone therapies and venous thromboembolism: where are we now?","volume":"9","author":"van Hylckama Vlieg","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0050","doi-asserted-by":"crossref","first-page":"d2151","DOI":"10.1136\/bmj.d2151","article-title":"Risk of non\u2010fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case\u2013control study using United States claims data","volume":"342","author":"Jick","year":"2011","journal-title":"BMJ"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0055","doi-asserted-by":"crossref","first-page":"d2139","DOI":"10.1136\/bmj.d2139","article-title":"Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case\u2013control study based on UK General Practice Research Database","volume":"342","author":"Parkin","year":"2011","journal-title":"BMJ"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0060","doi-asserted-by":"crossref","first-page":"E1319","DOI":"10.1503\/cmaj.110463","article-title":"Higher risk of venous thrombosis associated with drospirenone\u2010containing oral contraceptives: a population\u2010based cohort study","volume":"183","author":"Gronich","year":"2011","journal-title":"CMAJ"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0065","doi-asserted-by":"crossref","first-page":"d6423","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001\u20139","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0070","unstructured":"Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. 2012. Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM277384.pdf. Accessed 22 October 2011."},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0075","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(99)06092-4","article-title":"Low\u2010dose oral contraceptives and acquired resistance to activated protein\u00a0C: a randomised cross\u2010over study","volume":"354","author":"Rosing","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0080","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1111\/j.1538-7836.2004.00983.x","article-title":"Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate","volume":"2","author":"van Vliet","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0085","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1160\/TH07-07-0439","article-title":"Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography","volume":"98","author":"Tchaikovski","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0090","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2141.2003.04443.x","article-title":"Activated protein\u00a0C resistance determined with a thrombin generation\u2010based test predicts for venous thrombosis in men and women","volume":"122","author":"Tans","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0095","first-page":"482","article-title":"Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?","volume":"81","author":"Odlind","year":"2002","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0100","series-title":"Greenspan\u2019s Basic & Clinical Endocrinology","author":"Gardner","year":"2007"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0105","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0010-7824(90)90034-S","article-title":"Effects of seven low\u2010dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone","volume":"41","author":"van der Vange","year":"1990","journal-title":"Contraception"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0010-7824(00)00196-7","article-title":"Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel","volume":"63","author":"Knopp","year":"2001","journal-title":"Contraception"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0115","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2003-04-1285","article-title":"Effect of second\u2010 and third\u2010generation oral contraceptives on the protein\u00a0C system in the absence or presence of the factor\u00a0V Leiden mutation: a randomized trial","volume":"103","author":"Kemmeren","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0120","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9378(03)00950-5","article-title":"Sex hormone\u2010binding globulin \u2013 a surrogate marker for the prothrombotic effects of combined oral contraceptives","volume":"190","author":"van Rooijen","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0125","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1160\/TH08-09-0621","article-title":"The effect of the levonorgestrel\u2010releasing intrauterine system on the resistance to activated protein\u00a0C (APC)","volume":"101","author":"van Vliet","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0130","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.thromres.2007.08.010","article-title":"Sensitivity to activated protein\u00a0C during the menstrual cycle in women with and without factor\u00a0VLeiden","volume":"121","author":"van Vliet","year":"2008","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0135","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.thromres.2008.04.022","article-title":"Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross\u2010over study","volume":"123","author":"Fleischer","year":"2009","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0140","series-title":"Medical Eligibility Criteria for Contraceptive Use","year":"2009"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0145","unstructured":"Tchaikovski S. Hormone\u2010induced changes in the coagulation system. Thesis, Maastricht University, 2009. Universitaire Pers Maastricht, Maastricht, the Netherlands."},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0150","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/AOG.0b013e3181626d1b","article-title":"Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial","volume":"111","author":"Johnson","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0155","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.contraception.2009.07.004","article-title":"Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30\u2003mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism","volume":"81","author":"Jick","year":"2010","journal-title":"Contraception"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0160","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1161\/ATVBAHA.110.211482","article-title":"The risk of deep venous thrombosis associated with injectable depot\u2010medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device","volume":"30","author":"van Hylckama Vlieg","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0165","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.contraception.2006.01.001","article-title":"Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35\u2003microg of ethinyl estradiol","volume":"73","author":"Jick","year":"2006","journal-title":"Contraception"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0170","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.AOG.0000250968.82370.04","article-title":"Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users","volume":"109","author":"Cole","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0175","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.contraception.2007.03.003","article-title":"Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35\u2003\u03bcg of ethinyl estradiol","volume":"76","author":"Jick","year":"2007","journal-title":"Contraception"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0180","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003088-200039030-00005","article-title":"Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring","volume":"39","author":"Timmer","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0185","unstructured":"Ortho\u2010McNeil\u2010Janssen Pharmaceuticals. US product information ortho\u2010Evra\u00ae. 2009. http:\/\/www.orthoevra.com."},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0190","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/0091270006297919","article-title":"Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive","volume":"47","author":"Devineni","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0195","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.contraception.2008.04.004","article-title":"Sex hormone\u2010binding globulin: not a surrogate marker for venous thromboembolism in women using oral contraceptives","volume":"78","author":"Stanczyk","year":"2008","journal-title":"Contraception"},{"key":"10.1111\/j.1538-7836.2012.04720.x_bb0200","first-page":"1","article-title":"Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group","volume":"877","year":"1998","journal-title":"World Health Organ Tech Rep Ser"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2012.04720.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362206305X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362206305X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2012.04720.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:01:15Z","timestamp":1761534075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362206305X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S153878362206305X"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2012.04720.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex hormone\u2010binding globulin as a marker for the thrombotic risk of hormonal contraceptives","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2012.04720.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}